Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HGS Submits BLA For Interferon Zalbin For Hepatitis C

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, the interferon could offer a dosing advantage over pegylated interferons, although safety data could mean a bumpy regulatory road ahead.

You may also be interested in...



Novartis And HGS Close The Door On Zalbin

Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.

Novartis And HGS Close The Door On Zalbin

Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.

Merck And Vertex Poised For Growth In Singapore's HCV Market As Medical Tourism Booms

SHANGHAI - Novel hepatitis C treatments from Merck and Vertex are expected to fare well in Singapore - with the proper marketing campaigns - due in part to increased medical tourism from neighboring Southeast Asian countries

Related Content

Topics

UsernamePublicRestriction

Register

PS068805

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel